LACTOLOGY FOUNDATION

Sibutramine (ATC A08AA10) During Lactation

Sibutramine is a centrally acting anti-obesity medicine classified as ATC A08AA10. It should be avoided during breastfeeding because there is no published clinical experience on its use in lactation, no reported milk or infant serum concentrations, and significant maternal cardiovascular safety concerns.ncbi.nlm.nih+2

ATC class and general pharmacology

ATC code: A08AA10
International nonproprietary name: Sibutramine
ATC group: A08A — Antiobesity preparations, excluding diet products
Pharmacological subgroup: A08AA — Centrally acting antiobesity products
Defined daily dose: 10 mg orally.atcddd.fhi

Sibutramine is a centrally acting anorectic agent formerly used as an adjunct to dietary modification, behavioural intervention, and physical activity in the management of obesity. It reduces food intake primarily through monoamine reuptake inhibition rather than through direct amphetamine release.

The medicine and its pharmacologically active metabolites inhibit reuptake of norepinephrine and serotonin, with a smaller effect on dopamine reuptake. The resulting increase in synaptic monoaminergic signalling is associated with enhanced satiety, reduced hunger, and a modest increase in energy expenditure. However, increased noradrenergic activity also produces peripheral sympathomimetic effects, including increased heart rate and attenuation of the blood-pressure reduction normally associated with weight loss.pubmed.ncbi.nlm.nih+1

Sibutramine undergoes extensive first-pass hepatic metabolism. Its major active metabolites, commonly referred to as desmethylsibutramine and didesmethylsibutramine, contribute substantially to its pharmacological activity. Therefore, assessment of exposure should encompass the parent medicine and its active metabolites rather than the parent compound alone.

Although sibutramine was once prescribed for obesity, its regulatory status changed substantially after cardiovascular-outcome evidence emerged. The European Medicines Agency concluded that the benefits did not outweigh the risks and recommended suspension of marketing authorisations for sibutramine-containing medicines across the European Union.ema.europa

Toxicological profile

Sibutramine has a clinically significant toxicological profile, particularly involving cardiovascular, neurological, psychiatric, and interaction-related risks. Risk is influenced by dose, treatment duration, patient age, pre-existing cardiovascular disease, hypertension, psychiatric vulnerability, hepatic or renal impairment, and exposure to other medicines or stimulants.

Common or clinically relevant adverse effects may include:

• Dry mouth, constipation, nausea, reduced appetite, headache, and sweating.
• Insomnia, nervousness, agitation, anxiety, tremor, dizziness, and mood changes.
• Tachycardia, palpitations, increased blood pressure, and possible QT-interval prolongation.
• Worsening of pre-existing hypertension or increased cardiovascular strain.
• Potential exacerbation of psychiatric symptoms, including agitation or manic symptoms in predisposed individuals.

The principal safety concern is cardiovascular toxicity. Hypertension, tachycardia, arrhythmias, and myocardial infarction have been reported in sibutramine-treated patients. In the SCOUT cardiovascular-outcome trial, long-term sibutramine treatment in patients with pre-existing cardiovascular disease was associated with an increased risk of non-fatal myocardial infarction and non-fatal stroke.pubmed.ncbi.nlm.nih

The European Medicines Agency’s safety review concluded that sibutramine was associated with an increased risk of serious non-fatal cardiovascular events, including heart attack and stroke, compared with placebo, and recommended withdrawal from European Union markets.ema.europa

Sibutramine should be considered particularly inappropriate in patients with established coronary heart disease, previous stroke, heart failure, cardiac arrhythmia, or uncontrolled hypertension. It also presents potentially serious interaction risks with monoamine oxidase inhibitors, serotonergic antidepressants, certain migraine medicines, sympathomimetic agents, and other centrally acting weight-loss preparations. Combined serotonergic exposure may increase the risk of serotonin toxicity, while combined sympathetic stimulation may amplify hypertension, tachycardia, hyperthermia, and arrhythmia risk.

In overdose, clinically important manifestations may include marked tachycardia, hypertension, agitation, tremor, insomnia, confusion, seizures, cardiac rhythm disturbance, hyperthermia, and potentially life-threatening cardiovascular complications. Management is supportive and should include urgent toxicological and medical evaluation.

Lactation pharmacology and infant exposure

No published clinical studies have adequately measured sibutramine or its active metabolites in human milk. In addition, no published information is available on infant serum concentrations, estimated relative infant dose, or clinical outcomes in breastfed children exposed to sibutramine through maternal therapy. LactMed specifically reports that no published experience is available during breastfeeding and that no relevant information on maternal milk levels, infant levels, or effects in breastfed infants had been identified at the time of its review.ncbi.nlm.nih

The absence of direct evidence should not be interpreted as evidence of safety. Sibutramine is a lipophilic, centrally active medicine with active metabolites and clinically meaningful monoaminergic effects. These features create plausible potential for passage into human milk and for pharmacodynamic effects in a breastfed infant, especially when milk intake is high or infant metabolic clearance is limited.

Theoretical consequences of clinically relevant infant exposure include:

• Irritability, unusual wakefulness, disturbed sleep, restlessness, or excessive crying.
• Poor feeding, reduced sucking endurance, vomiting, or inadequate weight gain.
• Tremor, jitteriness, increased muscle tone, or exaggerated startle response.
• Tachycardia, sweating, pallor, increased blood pressure, or other signs of sympathetic stimulation.
• Less commonly, altered neurological state, hyperthermia, or seizures after substantial exposure.

Neonates, premature infants, infants with low birth weight, and infants with cardiac, neurological, hepatic, or renal disease should be regarded as particularly vulnerable. Their lower capacity for drug metabolism and elimination, together with higher milk intake relative to body mass, may increase the likelihood that low or moderate transfer could become clinically relevant.

Potential effects on milk production are not well characterized. However, maternal appetite suppression, inadequate caloric intake, insomnia, dehydration, anxiety, and cardiovascular adverse effects may undermine breastfeeding performance. Given the absence of direct lactation pharmacokinetic evidence, no reliable feeding-timing strategy or evidence-based washout period can be proposed for sibutramine.

Lactological safety assessment and clinical recommendations

Overall lactological assessment: Avoid during breastfeeding.

Sibutramine is not an appropriate routine treatment for weight management in breastfeeding women. The conclusion is based on the complete absence of direct lactation evidence, the presence of active metabolites, potential infant monoaminergic and cardiovascular stimulation, the inability to quantify infant exposure, and well-established maternal cardiovascular concerns. LactMed recommends that an alternative therapy be preferred, particularly when nursing a newborn or premature infant.ncbi.nlm.nih

Clinical recommendations

1. Do not initiate sibutramine during breastfeeding.
   Sibutramine should not be started for postpartum weight reduction while breastfeeding is ongoing. This recommendation is particularly strong during exclusive breastfeeding and when the infant is newborn, premature, low birth weight, or medically fragile.
2. Recognize its limited regulatory role.
   In the European Union, sibutramine marketing authorisations were suspended after evidence that cardiovascular risks outweighed its weight-loss benefits. A breastfeeding patient should therefore not be exposed to sibutramine through prescribed, imported, internet-purchased, compounded, or adulterated weight-loss products.ema.europa
3. Use safer postpartum strategies.
   First-line management should include gradual nutritionally adequate weight reduction, dietary counselling, postpartum-appropriate physical activity, sleep and mental-health support, and assessment for metabolic or endocrine contributors to weight retention.
4. Review existing exposure immediately.
   If sibutramine use is identified in a breastfeeding patient, the prescribing clinician and the infant’s paediatric clinician should be contacted promptly. The clinical assessment should document the product source, dose, duration, time of the last dose, co-medications, stimulant or caffeine use, maternal symptoms, infant age, prematurity, and proportion of milk feeding.
5. Do not use breastfeed timing as a risk-control method.
   Feeding immediately before a dose, skipping a single feed, or expressing and discarding milk for a short interval cannot be considered reliable. The parent medicine has active metabolites, milk kinetics are unknown, and there is no validated relative infant dose or milk-clearance interval.ncbi.nlm.nih
6. Individualize temporary interruption decisions.
   When maternal treatment or clinically significant exposure has occurred, decisions on temporary interruption of breastfeeding, expression of milk, alternative infant feeding, and timing of resumption should be made with specialist medicines-in-lactation, clinical toxicology, and paediatric input.
7. Monitor a potentially exposed infant.
   Monitor feeding, wakefulness, sleep, irritability, tremor, vomiting, weight gain, pallor, sweating, and apparent heart-rate abnormalities. Urgent paediatric assessment is required for marked agitation, poor feeding with reduced urine output, persistent vomiting, breathing difficulty, abnormal movements, fever, lethargy, or a suspected cardiovascular symptom.